Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Granulopoiesis and Neutrophil Homeostasis: A Metabolic, Daily Balancing Act.

Yvan-Charvet L, Ng LG.

Trends Immunol. 2019 Jul;40(7):598-612. doi: 10.1016/j.it.2019.05.004. Review.

PMID:
31256783
2.

Mesothelial cell CSF1 sustains peritoneal macrophage proliferation.

Ivanov S, Gallerand A, Gros M, Stunault MI, Merlin J, Vaillant N, Yvan-Charvet L, Guinamard RR.

Eur J Immunol. 2019 Jun 28. doi: 10.1002/eji.201948164. [Epub ahead of print]

PMID:
31251389
3.

Immunometabolic function of cholesterol in cardiovascular disease and beyond.

Yvan-Charvet L, Bonacina F, Guinamard RR, Norata GD.

Cardiovasc Res. 2019 Jul 1;115(9):1393-1407. doi: 10.1093/cvr/cvz127.

PMID:
31095280
4.

Immunometabolism of Phagocytes and Relationships to Cardiac Repair.

Zhang S, Bories G, Lantz C, Emmons R, Becker A, Liu E, Abecassis MM, Yvan-Charvet L, Thorp EB.

Front Cardiovasc Med. 2019 Apr 11;6:42. doi: 10.3389/fcvm.2019.00042. eCollection 2019. Review.

5.

Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer.

Guilbaud E, Gautier EL, Yvan-Charvet L.

Cancers (Basel). 2019 Mar 2;11(3). pii: E298. doi: 10.3390/cancers11030298. Review.

6.

The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again.

Hofman P, Ayache N, Barbry P, Barlaud M, Bel A, Blancou P, Checler F, Chevillard S, Cristofari G, Demory M, Esnault V, Falandry C, Gilson E, Guérin O, Glaichenhaus N, Guigay J, Ilié M, Mari B, Marquette CH, Paquis-Flucklinger V, Prate F, Saintigny P, Seitz-Polsky B, Skhiri T, Van Obberghen-Schilling E, Van Obberghen E, Yvan-Charvet L.

Cancers (Basel). 2019 Feb 21;11(2). pii: E250. doi: 10.3390/cancers11020250.

7.

Efferocytosis Fuels Requirements of Fatty Acid Oxidation and the Electron Transport Chain to Polarize Macrophages for Tissue Repair.

Zhang S, Weinberg S, DeBerge M, Gainullina A, Schipma M, Kinchen JM, Ben-Sahra I, Gius DR, Yvan-Charvet L, Chandel NS, Schumacker PT, Thorp EB.

Cell Metab. 2019 Feb 5;29(2):443-456.e5. doi: 10.1016/j.cmet.2018.12.004. Epub 2018 Dec 27.

PMID:
30595481
8.

Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque.

Shea S, Stein JH, Jorgensen NW, McClelland RL, Tascau L, Shrager S, Heinecke JW, Yvan-Charvet L, Tall AR.

Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):89-96. doi: 10.1161/ATVBAHA.118.311366.

9.

Rab4b Deficiency in T Cells Promotes Adipose Treg/Th17 Imbalance, Adipose Tissue Dysfunction, and Insulin Resistance.

Gilleron J, Bouget G, Ivanov S, Meziat C, Ceppo F, Vergoni B, Djedaini M, Soprani A, Dumas K, Jacquel A, Yvan-Charvet L, Venteclef N, Tanti JF, Cormont M.

Cell Rep. 2018 Dec 18;25(12):3329-3341.e5. doi: 10.1016/j.celrep.2018.11.083.

10.

Is defective cholesterol efflux an integral inflammatory component in myelopoiesis-driven cardiovascular diseases?

Yvan-Charvet L, Swirski FK.

Eur Heart J. 2018 Jun 14;39(23):2168-2171. doi: 10.1093/eurheartj/ehy269. No abstract available.

PMID:
29771312
11.

Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.

Ohanna M, Cerezo M, Nottet N, Bille K, Didier R, Beranger G, Mograbi B, Rocchi S, Yvan-Charvet L, Ballotti R, Bertolotto C.

Genes Dev. 2018 Mar 1;32(5-6):448-461. doi: 10.1101/gad.305854.117. Epub 2018 Mar 22.

12.

Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies.

Yvan-Charvet L, Cariou B.

Curr Opin Lipidol. 2018 Jun;29(3):246-258. doi: 10.1097/MOL.0000000000000505.

PMID:
29553996
13.

Lysosomal Cholesterol Hydrolysis Couples Efferocytosis to Anti-Inflammatory Oxysterol Production.

Viaud M, Ivanov S, Vujic N, Duta-Mare M, Aira LE, Barouillet T, Garcia E, Orange F, Dugail I, Hainault I, Stehlik C, Marchetti S, Boyer L, Guinamard R, Foufelle F, Bochem A, Hovingh KG, Thorp EB, Gautier EL, Kratky D, Dasilva-Jardine P, Yvan-Charvet L.

Circ Res. 2018 May 11;122(10):1369-1384. doi: 10.1161/CIRCRESAHA.117.312333. Epub 2018 Mar 9.

14.

Cholesterol Accumulation in Dendritic Cells Links the Inflammasome to Acquired Immunity.

Westerterp M, Gautier EL, Ganda A, Molusky MM, Wang W, Fotakis P, Wang N, Randolph GJ, D'Agati VD, Yvan-Charvet L, Tall AR.

Cell Metab. 2017 Jun 6;25(6):1294-1304.e6. doi: 10.1016/j.cmet.2017.04.005. Epub 2017 May 4.

15.

Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD.

Ganda A, Yvan-Charvet L, Zhang Y, Lai EJ, Regunathan-Shenk R, Hussain FN, Avasare R, Chakraborty B, Febus AJ, Vernocchi L, Lantigua R, Wang Y, Shi X, Hsieh J, Murphy AJ, Wang N, Bijl N, Gordon KM, de Miguel MH, Singer JR, Hogan J, Cremers S, Magnusson M, Melander O, Gerszten RE, Tall AR.

J Mol Cell Cardiol. 2017 Nov;112:114-122. doi: 10.1016/j.yjmcc.2017.05.001. Epub 2017 May 4.

16.

Can LDL cholesterol be too low? Possible risks of extremely low levels.

Olsson AG, Angelin B, Assmann G, Binder CJ, Björkhem I, Cedazo-Minguez A, Cohen J, von Eckardstein A, Farinaro E, Müller-Wieland D, Parhofer KG, Parini P, Rosenson RS, Starup-Linde J, Tikkanen MJ, Yvan-Charvet L.

J Intern Med. 2017 Jun;281(6):534-553. doi: 10.1111/joim.12614. Review.

17.

The modern interleukin-1 superfamily: Divergent roles in obesity.

Lee MK, Yvan-Charvet L, Masters SL, Murphy AJ.

Semin Immunol. 2016 Oct;28(5):441-449. doi: 10.1016/j.smim.2016.10.001. Epub 2016 Oct 7. Review.

PMID:
27726910
18.

HIF-2α in Resting Macrophages Tempers Mitochondrial Reactive Oxygen Species To Selectively Repress MARCO-Dependent Phagocytosis.

Dehn S, DeBerge M, Yeap XY, Yvan-Charvet L, Fang D, Eltzschig HK, Miller SD, Thorp EB.

J Immunol. 2016 Nov 1;197(9):3639-3649. Epub 2016 Sep 26.

19.

Disruption of Glut1 in Hematopoietic Stem Cells Prevents Myelopoiesis and Enhanced Glucose Flux in Atheromatous Plaques of ApoE(-/-) Mice.

Sarrazy V, Viaud M, Westerterp M, Ivanov S, Giorgetti-Peraldi S, Guinamard R, Gautier EL, Thorp EB, De Vivo DC, Yvan-Charvet L.

Circ Res. 2016 Apr 1;118(7):1062-77. doi: 10.1161/CIRCRESAHA.115.307599. Epub 2016 Feb 29.

20.

Maintenance of Macrophage Redox Status by ChREBP Limits Inflammation and Apoptosis and Protects against Advanced Atherosclerotic Lesion Formation.

Sarrazy V, Sore S, Viaud M, Rignol G, Westerterp M, Ceppo F, Tanti JF, Guinamard R, Gautier EL, Yvan-Charvet L.

Cell Rep. 2015 Oct 6;13(1):132-144. doi: 10.1016/j.celrep.2015.08.068. Epub 2015 Sep 24.

21.

Adipose modulation of ABCG1 uncovers an intimate link between sphingomyelin and triglyceride storage.

Murphy AJ, Yvan-Charvet L.

Diabetes. 2015 Mar;64(3):689-92. doi: 10.2337/db14-1553. No abstract available.

22.

Cholesterol, inflammation and innate immunity.

Tall AR, Yvan-Charvet L.

Nat Rev Immunol. 2015 Feb;15(2):104-16. doi: 10.1038/nri3793. Review.

23.

Understanding macrophage diversity at the ontogenic and transcriptomic levels.

Gautier EL, Yvan-Charvet L.

Immunol Rev. 2014 Nov;262(1):85-95. doi: 10.1111/imr.12231. Review.

PMID:
25319329
24.

Deficiency of ATP-binding cassette transporter B6 in megakaryocyte progenitors accelerates atherosclerosis in mice.

Murphy AJ, Sarrazy V, Wang N, Bijl N, Abramowicz S, Westerterp M, Welch CB, Schuetz JD, Yvan-Charvet L.

Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):751-8. doi: 10.1161/ATVBAHA.113.302613. Epub 2014 Feb 6.

PMID:
24504733
25.

ATP-binding cassette transporters, atherosclerosis, and inflammation.

Westerterp M, Bochem AE, Yvan-Charvet L, Murphy AJ, Wang N, Tall AR.

Circ Res. 2014 Jan 3;114(1):157-70. doi: 10.1161/CIRCRESAHA.114.300738. Review.

PMID:
24385509
26.

Liver X receptor α-dependent iron handling in M2 macrophages: The missing link between cholesterol and intraplaque hemorrhage?

Hasty AH, Yvan-Charvet L.

Circ Res. 2013 Nov 8;113(11):1182-5. doi: 10.1161/CIRCRESAHA.113.302613. No abstract available.

PMID:
24201110
27.

Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis.

Murphy AJ, Bijl N, Yvan-Charvet L, Welch CB, Bhagwat N, Reheman A, Wang Y, Shaw JA, Levine RL, Ni H, Tall AR, Wang N.

Nat Med. 2013 May;19(5):586-94. doi: 10.1038/nm.3150. Epub 2013 Apr 14.

28.

Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice.

Westerterp M, Murphy AJ, Wang M, Pagler TA, Vengrenyuk Y, Kappus MS, Gorman DJ, Nagareddy PR, Zhu X, Abramowicz S, Parks JS, Welch C, Fisher EA, Wang N, Yvan-Charvet L, Tall AR.

Circ Res. 2013 May 24;112(11):1456-65. doi: 10.1161/CIRCRESAHA.113.301086. Epub 2013 Apr 9.

29.

Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis.

Ganda A, Magnusson M, Yvan-Charvet L, Hedblad B, Engström G, Ai D, Wang TJ, Gerszten RE, Melander O, Tall AR.

Circulation. 2013 Mar 5;127(9):988-96. doi: 10.1161/CIRCULATIONAHA.112.000682. Epub 2013 Feb 1.

30.

HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders.

Gautier EL, Westerterp M, Bhagwat N, Cremers S, Shih A, Abdel-Wahab O, Lütjohann D, Randolph GJ, Levine RL, Tall AR, Yvan-Charvet L.

J Exp Med. 2013 Feb 11;210(2):339-53. doi: 10.1084/jem.20121357. Epub 2013 Jan 14.

31.

Cholesterol efflux: a novel regulator of myelopoiesis and atherogenesis.

Tall AR, Yvan-Charvet L, Westerterp M, Murphy AJ.

Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2547-52. doi: 10.1161/ATVBAHA.112.300134. Review.

PMID:
23077140
32.

Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways.

Westerterp M, Gourion-Arsiquaud S, Murphy AJ, Shih A, Cremers S, Levine RL, Tall AR, Yvan-Charvet L.

Cell Stem Cell. 2012 Aug 3;11(2):195-206. doi: 10.1016/j.stem.2012.04.024.

33.

Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.

Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L.

Circulation. 2012 Apr 17;125(15):1905-19. doi: 10.1161/CIRCULATIONAHA.111.066589. Review. No abstract available.

34.

ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice.

Murphy AJ, Akhtari M, Tolani S, Pagler T, Bijl N, Kuo CL, Wang M, Sanson M, Abramowicz S, Welch C, Bochem AE, Kuivenhoven JA, Yvan-Charvet L, Tall AR.

J Clin Invest. 2011 Oct;121(10):4138-49. doi: 10.1172/JCI57559.

35.

Cdkn2a is an atherosclerosis modifier locus that regulates monocyte/macrophage proliferation.

Kuo CL, Murphy AJ, Sayers S, Li R, Yvan-Charvet L, Davis JZ, Krishnamurthy J, Liu Y, Puig O, Sharpless NE, Tall AR, Welch CL.

Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2483-92. doi: 10.1161/ATVBAHA.111.234492.

36.

Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells.

Murphy AJ, Westerterp M, Yvan-Charvet L, Tall AR.

Biochim Biophys Acta. 2012 Mar;1821(3):513-21. doi: 10.1016/j.bbalip.2011.08.003. Epub 2011 Aug 16. Review.

37.

[HDL and its transporters ABCA1 and ABCG1 regulate innate immunity and hematopoietic stem cell proliferation].

Gautier EL, Yvan-Charvet L.

Med Sci (Paris). 2011 Jan;27(1):9-11. doi: 10.1051/medsci/20112719. French. No abstract available.

38.

Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity.

Yvan-Charvet L, Quignard-Boulangé A.

Kidney Int. 2011 Jan;79(2):162-8. doi: 10.1038/ki.2010.391. Epub 2010 Oct 13. Review.

39.

ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase.

Terasaka N, Westerterp M, Koetsveld J, Fernández-Hernando C, Yvan-Charvet L, Wang N, Sessa WC, Tall AR.

Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2219-25. doi: 10.1161/ATVBAHA.110.213215. Epub 2010 Aug 26.

40.

ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation.

Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, Welch CL, Wang N, Randolph GJ, Snoeck HW, Tall AR.

Science. 2010 Jun 25;328(5986):1689-93. doi: 10.1126/science.1189731. Epub 2010 May 20.

41.

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.

Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR.

Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1430-8. doi: 10.1161/ATVBAHA.110.207142. Epub 2010 May 6.

42.

ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis.

Yvan-Charvet L, Pagler TA, Seimon TA, Thorp E, Welch CL, Witztum JL, Tabas I, Tall AR.

Circ Res. 2010 Jun 25;106(12):1861-9. doi: 10.1161/CIRCRESAHA.110.217281. Epub 2010 Apr 29.

43.

Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses.

Yvan-Charvet L, Wang N, Tall AR.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):139-43. doi: 10.1161/ATVBAHA.108.179283. Epub 2009 Oct 1. Review.

44.

Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue.

Yvan-Charvet L, Massiéra F, Lamandé N, Ailhaud G, Teboul M, Moustaid-Moussa N, Gasc JM, Quignard-Boulangé A.

Endocrinology. 2009 Mar;150(3):1421-8. doi: 10.1210/en.2008-1120. Epub 2008 Oct 23.

PMID:
18948399
45.

ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet.

Terasaka N, Yu S, Yvan-Charvet L, Wang N, Mzhavia N, Langlois R, Pagler T, Li R, Welch CL, Goldberg IJ, Tall AR.

J Clin Invest. 2008 Nov;118(11):3701-13. doi: 10.1172/JCI35470. Epub 2008 Oct 16.

46.

Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions.

Yvan-Charvet L, Welch C, Pagler TA, Ranalletta M, Lamkanfi M, Han S, Ishibashi M, Li R, Wang N, Tall AR.

Circulation. 2008 Oct 28;118(18):1837-47. doi: 10.1161/CIRCULATIONAHA.108.793869. Epub 2008 Oct 13.

47.

HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis.

Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N.

Cell Metab. 2008 May;7(5):365-75. doi: 10.1016/j.cmet.2008.03.001. Review.

48.

[Raising HDL-cholesterol: the future drug therapy for atherosclerosis?].

Masson D, Yvan-Charvet L.

Med Sci (Paris). 2008 Apr;24(4):341-3. doi: 10.1051/medsci/2008244341. French. No abstract available.

49.

ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain.

Wang N, Yvan-Charvet L, Lütjohann D, Mulder M, Vanmierlo T, Kim TW, Tall AR.

FASEB J. 2008 Apr;22(4):1073-82. Epub 2007 Nov 26.

PMID:
18039927
50.

Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice.

Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C, Tall AR.

J Clin Invest. 2007 Dec;117(12):3900-8.

Supplemental Content

Loading ...
Support Center